105 related articles for article (PubMed ID: 24680060)
41. Conformational flexibility of beta-secretase: molecular dynamics simulation and essential dynamics analysis.
Xiong B; Huang XQ; Shen LL; Shen JH; Luo XM; Shen X; Jiang HL; Chen KX
Acta Pharmacol Sin; 2004 Jun; 25(6):705-13. PubMed ID: 15169620
[TBL] [Abstract][Full Text] [Related]
42. BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.
Clarke B; Cutler L; Demont E; Dingwall C; Dunsdon R; Hawkins J; Howes C; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
Bioorg Med Chem Lett; 2010 Aug; 20(15):4639-44. PubMed ID: 20579874
[TBL] [Abstract][Full Text] [Related]
43. Inhibitor binding to the plasmepsin IV aspartic protease from Plasmodium falciparum.
Gutiérrez-de-Terán H; Nervall M; Ersmark K; Liu P; Janka LK; Dunn B; Hallberg A; Aqvist J
Biochemistry; 2006 Sep; 45(35):10529-41. PubMed ID: 16939205
[TBL] [Abstract][Full Text] [Related]
44. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
Calugi C; Guarna A; Trabocchi A
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
[TBL] [Abstract][Full Text] [Related]
45. Design of potent aspartic protease inhibitors to treat various diseases.
Nguyen JT; Hamada Y; Kimura T; Kiso Y
Arch Pharm (Weinheim); 2008 Sep; 341(9):523-35. PubMed ID: 18763714
[TBL] [Abstract][Full Text] [Related]
46. A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems.
Pescarolo MP; Bagnasco L; Malacarne D; Melchiori A; Valente P; Millo E; Bruno S; Basso S; Parodi S
FASEB J; 2001 Jan; 15(1):31-33. PubMed ID: 11099487
[TBL] [Abstract][Full Text] [Related]
47. Total chemical synthesis of human T-cell leukemia virus type 1 protease via native chemical ligation.
Li C; Li X; Lu W
Biopolymers; 2010; 94(4):487-94. PubMed ID: 20593478
[TBL] [Abstract][Full Text] [Related]
48. Stabilization from autoproteolysis and kinetic characterization of the human T-cell leukemia virus type 1 proteinase.
Louis JM; Oroszlan S; Tözsér J
J Biol Chem; 1999 Mar; 274(10):6660-6. PubMed ID: 10037763
[TBL] [Abstract][Full Text] [Related]
49. Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.
Kuhnert M; Steuber H; Diederich WE
J Med Chem; 2014 Jul; 57(14):6266-72. PubMed ID: 25006983
[TBL] [Abstract][Full Text] [Related]
50. Crystal structure of aspartic proteinase from Irpex lacteus in complex with inhibitor pepstatin.
Fujimoto Z; Fujii Y; Kaneko S; Kobayashi H; Mizuno H
J Mol Biol; 2004 Aug; 341(5):1227-35. PubMed ID: 15321718
[TBL] [Abstract][Full Text] [Related]
51. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: implications for the design of antifungal agents.
Abad-Zapatero C; Goldman R; Muchmore SW; Hutchins C; Stewart K; Navaza J; Payne CD; Ray TL
Protein Sci; 1996 Apr; 5(4):640-52. PubMed ID: 8845753
[TBL] [Abstract][Full Text] [Related]
52. Dissection of the pH dependence of inhibitor binding energetics for an aspartic protease: direct measurement of the protonation states of the catalytic aspartic acid residues.
Xie D; Gulnik S; Collins L; Gustchina E; Suvorov L; Erickson JW
Biochemistry; 1997 Dec; 36(51):16166-72. PubMed ID: 9405050
[TBL] [Abstract][Full Text] [Related]
53. KMI-358 and KMI-370, highly potent and small-sized BACE1 inhibitors containing phenylnorstatine.
Kimura T; Shuto D; Kasai S; Liu P; Hidaka K; Hamada T; Hayashi Y; Hattori C; Asai M; Kitazume S; Saido TC; Ishiura S; Kiso Y
Bioorg Med Chem Lett; 2004 Mar; 14(6):1527-31. PubMed ID: 15006396
[TBL] [Abstract][Full Text] [Related]
54. Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.
Charrier N; Clarke B; Cutler L; Demont E; Dingwall C; Dunsdon R; Hawkins J; Howes C; Hubbard J; Hussain I; Maile G; Matico R; Mosley J; Naylor A; O'Brien A; Redshaw S; Rowland P; Soleil V; Smith KJ; Sweitzer S; Theobald P; Vesey D; Walter DS; Wayne G
Bioorg Med Chem Lett; 2009 Jul; 19(13):3664-8. PubMed ID: 19428244
[TBL] [Abstract][Full Text] [Related]
55. Proteolytic processing of the human T-cell lymphotropic virus 1 reverse transcriptase: identification of the N-terminal cleavage site by mass spectrometry.
Agbuya PG; Sherman NE; Moen LK
Arch Biochem Biophys; 2001 Aug; 392(1):93-102. PubMed ID: 11469799
[TBL] [Abstract][Full Text] [Related]
56. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
[TBL] [Abstract][Full Text] [Related]
57. Inhibitors of aspartic proteases in human diseases: molecular modeling comes of age.
Hoegl L; Korting HC; Klebe G
Pharmazie; 1999 May; 54(5):319-29. PubMed ID: 10368824
[TBL] [Abstract][Full Text] [Related]
58. Molecular replacement with pseudosymmetry and model dissimilarity: a case study.
Jaskólski M; Li M; Laco G; Gustchina A; Wlodawer A
Acta Crystallogr D Biol Crystallogr; 2006 Feb; 62(Pt 2):208-15. PubMed ID: 16421452
[TBL] [Abstract][Full Text] [Related]
59. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
[TBL] [Abstract][Full Text] [Related]
60. Proteases universally recognize beta strands in their active sites.
Tyndall JD; Nall T; Fairlie DP
Chem Rev; 2005 Mar; 105(3):973-99. PubMed ID: 15755082
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
